{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T14:27:26Z","timestamp":1784989646895,"version":"3.55.0"},"reference-count":37,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T00:00:00Z","timestamp":1771027200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"the National Key R&D Program of China","award":["2023YFC2706300"],"award-info":[{"award-number":["2023YFC2706300"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Familial partial lipodystrophy type 3 (FPLD3) is a rare autosomal dominant disorder caused by mutations in peroxisome proliferator-activated receptor gamma(PPARG), which encodes the key adipogenic transcription factor peroxisome proliferator-activated receptor gamma(PPAR\u03b3). Clinical diagnosis is challenging due to phenotypic overlap with common metabolic syndromes. We identified a novel PPARG variant in a Chinese family and performed comprehensive functional characterization to elucidate its pathogenic mechanism. The proband, a 15-year-old boy presenting with atypical fat distribution, severe insulin resistance, hypertriglyceridemia, and pancreatitis, underwent clinical evaluation and whole-exome sequencing. The identified variant was confirmed by Sanger sequencing. Its functional impact was assessed through in silico modeling, luciferase reporter assays, protein stability analysis (cycloheximide chase), and evaluation of mitochondrial function (JC-1 staining) and adipocyte gene expression in cellular models. A heterozygous PPARG c.634C&gt;T (p.Arg212Trp, R212W) variant was identified and segregated with the phenotype. Functional studies revealed that the R212W mutant exhibits a partial loss of transcriptional activity (~40% of wild-type) while retaining ligand sensitivity. Crucially, we demonstrated that the mutant protein has significantly reduced stability due to accelerated degradation. In adipocyte models, R212W expression led to impaired mitochondrial membrane potential, depleted cellular ATP levels, and downregulated expression of key metabolic genes (glucose transporter 4[GLUT4], adiponectin[ADIPOQ], fatty acid binding protein 4[FABP4], lipoprotein lipase[LPL], perilipin 1[PLIN1]). These functional deficits were partially rescued by treatment with the PPAR\u03b3 agonist rosiglitazone. We report a novel pathogenic PPARG R212W variant associated with FPLD3. Our data extend beyond a simple loss-of-function model by establishing a multi-faceted pathogenic mechanism involving protein destabilization, mitochondrial dysfunction, and cellular bioenergetic failure. The partial rescue by rosiglitazone suggests a potential therapeutic avenue. This study underscores the importance of integrating clinical phenotyping with deep functional analysis to diagnose and understand rare monogenic lipodystrophies.<\/jats:p>","DOI":"10.3390\/ijms27041851","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T10:14:32Z","timestamp":1771236872000},"page":"1851","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A Novel PPARG R212W Variant Causes Familial Partial Lipodystrophy Type 3: Clinical Presentation and Functional Characterization"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-7280-7670","authenticated-orcid":false,"given":"Yuan","family":"Gao","sequence":"first","affiliation":[{"name":"Hubei Provincial Key Laboratory of Pediatric Genetic Metabolic and Endocrine Rare Diseases, Hubei Provincial Clinical Research Center for Children\u2019s Growth and Development and Metabolic Diseases, Department of Pediatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9263-0400","authenticated-orcid":false,"given":"Ningyi","family":"Song","sequence":"additional","affiliation":[{"name":"Hubei Provincial Key Laboratory of Pediatric Genetic Metabolic and Endocrine Rare Diseases, Hubei Provincial Clinical Research Center for Children\u2019s Growth and Development and Metabolic Diseases, Department of Pediatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4727-8507","authenticated-orcid":false,"given":"Lina","family":"Fu","sequence":"additional","affiliation":[{"name":"Hubei Provincial Key Laboratory of Pediatric Genetic Metabolic and Endocrine Rare Diseases, Hubei Provincial Clinical Research Center for Children\u2019s Growth and Development and Metabolic Diseases, Department of Pediatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Liang","sequence":"additional","affiliation":[{"name":"Hubei Provincial Key Laboratory of Pediatric Genetic Metabolic and Endocrine Rare Diseases, Hubei Provincial Clinical Research Center for Children\u2019s Growth and Development and Metabolic Diseases, Department of Pediatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3748-4817","authenticated-orcid":false,"given":"Xiaoping","family":"Luo","sequence":"additional","affiliation":[{"name":"Hubei Provincial Key Laboratory of Pediatric Genetic Metabolic and Endocrine Rare Diseases, Hubei Provincial Clinical Research Center for Children\u2019s Growth and Development and Metabolic Diseases, Department of Pediatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"American Diabetes Association (2011). Diagnosis and classification of diabetes mellitus. Diabetes Care, 34, S62\u2013S69.","DOI":"10.2337\/dc11-S062"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.pathol.2018.11.004","article-title":"Lipodystrophies, dyslipidaemias and atherosclerotic cardiovascular disease","volume":"51","author":"Hussain","year":"2019","journal-title":"Pathology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.metabol.2017.04.010","article-title":"Clinical presentations, metabolic abnormalities and end-organ complications in patients with familial partial lipodystrophy","volume":"72","author":"Akinci","year":"2017","journal-title":"Metabolism"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e142244","DOI":"10.1172\/JCI142244","article-title":"Monogenic diabetes: A gateway to precision medicine in diabetes","volume":"131","author":"Zhang","year":"2021","journal-title":"J. Clin. Investig."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/47254","article-title":"Dominant negative mutations in human PPAR\u03b3 associated with severe insulin resistance, diabetes mellitus and hypertension","volume":"402","author":"Barroso","year":"1999","journal-title":"Nature"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1677\/JOE-10-0272","article-title":"Lipodystrophy: Metabolic insights from a rare disorder","volume":"207","author":"Sleigh","year":"2010","journal-title":"J. Endocrinol."},{"key":"ref_7","first-page":"576","article-title":"The diagnosis and management of lipodystrophy syndromes: A multi-society practice guideline","volume":"12","author":"Brown","year":"2016","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.1210\/jc.2011-1159","article-title":"Lipodystrophies: Genetic and acquired body fat disorders","volume":"96","author":"Garg","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/nrendo.2010.199","article-title":"Lipodystrophy: Pathophysiology and advances in treatment","volume":"7","author":"Fiorenza","year":"2011","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1172\/JCI28003","article-title":"PPAR\u03b3 and human metabolic disease","volume":"116","author":"Semple","year":"2006","journal-title":"J. Clin. Investig."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/978-1-60761-500-2_29","article-title":"PPARgamma and the pathobiology of pulmonary arterial hypertension","volume":"661","author":"Rabinovitch","year":"2010","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Soares, R.M.V., da Silva, M.A., Campos, J.T.A.D.M., and Lima, J.G. (2024). Familial partial lipodystrophy resulting from loss-of-function PPAR\u03b3 pathogenic variants: Phenotypic, clinical, and genetic features. Front. Endocrinol., 15.","DOI":"10.3389\/fendo.2024.1394102"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.cmet.2006.09.003","article-title":"Non-DNA binding, dominant-negative, human PPAR\u03b3 mutations cause lipodystrophic insulin resistance","volume":"4","author":"Agostini","year":"2006","journal-title":"Cell Metab."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1007487","article-title":"Perilipin deficiency and autosomal dominant partial lipodystrophy","volume":"364","author":"Gandotra","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1172\/JCI21752","article-title":"Mitochondrial remodeling in adipose tissue associated with obesity and treatment with rosiglitazone","volume":"114","author":"Nicoloro","year":"2004","journal-title":"J. Clin. Investig."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.2337\/diabetes.54.5.1392","article-title":"Pioglitazone induces mitochondrial biogenesis in human subcutaneous adipose tissue in vivo","volume":"54","author":"Bogacka","year":"2005","journal-title":"Diabetes"},{"key":"ref_17","first-page":"6","article-title":"PPAR family and its relationship to metabolic syndrome","volume":"36","author":"Zhang","year":"2005","journal-title":"Sheng Li Ke Xue Jin Zhan"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1194\/jlr.P025437","article-title":"Clinical and molecular characterization of a severe form of partial lipodystrophy expanding the phenotype of PPAR\u03b3 deficiency","volume":"53","author":"Campeau","year":"2012","journal-title":"J. Lipid Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2337\/diabetes.47.4.507","article-title":"PPAR-gamma: Adipogenic regulator and thiazolidinedione receptor","volume":"47","author":"Spiegelman","year":"1998","journal-title":"Diabetes"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s13098-024-01387-9","article-title":"Case report: Two novel PPARG pathogenic variants associated with type 3 familial partial lipodystrophy in Brazil","volume":"16","author":"Soares","year":"2024","journal-title":"Diabetol. Metab. Syndr."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.jacl.2020.05.039","article-title":"Familial Partial Lipodystrophy Due to a Mutation in Pparg Resulting in Severe Hypertriglyceridemia, Hepatosteatosis and Insulin Resistance","volume":"14","author":"Bajaj","year":"2020","journal-title":"J. Clin. Lipidol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1210\/jc.2006-1807","article-title":"Familial partial lipodystrophy phenotype resulting from a single-base mutation in deoxyribonucleic acid-binding domain of peroxisome proliferator-activated receptor-\u03b3","volume":"92","author":"Monajemi","year":"2007","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Rutkowska, L., Salachna, D., Lewandowski, K., Lewi\u0144ski, A., and Gach, A. (2022). Familial Partial Lipodystrophy-Literature Review and Report of a Novel Variant in PPARG Expanding the Spectrum of Disease-Causing Alterations in FPLD3. Diagnostics, 12.","DOI":"10.3390\/diagnostics12051122"},{"key":"ref_24","first-page":"715","article-title":"Gene-gene and gene-environment interactions in lipodystrophy: Lessons learned from natural PPAR\u03b3 mutants","volume":"1864","author":"Broekema","year":"2019","journal-title":"Biochim. Biophys. Acta (BBA)-Mol. Cell Biol. Lipids"},{"key":"ref_25","first-page":"649","article-title":"Peroxisome proliferator-activated receptors: Nuclear control of metabolism","volume":"20","author":"Desvergne","year":"1999","journal-title":"Endocr. Rev."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"7090","DOI":"10.1038\/s41467-022-34766-9","article-title":"PPAR\u03b3 lipodystrophy mutants reveal intermolecular interactions required for enhancer activation","volume":"13","author":"Madsen","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Lambadiari, V., Kountouri, A., Maratou, E., Liatis, S., Dimitriadis, G.D., and Karpe, F. (2021). Case Report: Metreleptin Treatment in a Patient With a Novel Mutation for Familial Partial Lipodystrophy Type 3, Presenting With Uncontrolled Diabetes and Insulin Resistance. Front. Endocrinol., 12.","DOI":"10.3389\/fendo.2021.684182"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1080\/14737159.2020.1730179","article-title":"Review of current status of molecular diagnosis and characterization of monogenic diabetes mellitus: A focus on next-generation sequencing","volume":"20","author":"Campbell","year":"2020","journal-title":"Expert. Rev. Mol. Diagn."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11892-018-0982-8","article-title":"Clinical Management of Women with Monogenic Diabetes During Pregnancy","volume":"18","author":"Dickens","year":"2018","journal-title":"Curr. Diab Rep."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/cr.2010.13","article-title":"PPARs: Diverse regulators in energy metabolism and metabolic diseases","volume":"20","author":"Wang","year":"2010","journal-title":"Cell Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/ng.3700","article-title":"Prospective functional classification of all possible missense variants in PPARG","volume":"48","author":"Majithia","year":"2016","journal-title":"Nat. Genet."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","article-title":"Highly accurate protein structure prediction with AlphaFold","volume":"596","author":"Jumper","year":"2021","journal-title":"Nature"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1136\/jmg.2010.082081","article-title":"GeneScreen: A program for high-throughput mutation detection in DNA sequence electropherograms","volume":"48","author":"Carr","year":"2011","journal-title":"J. Med. Genet."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"16664","DOI":"10.1074\/jbc.M110.112805","article-title":"Long chain acyl-CoA synthetase-3 is a molecular target for peroxisome proliferator-activated receptor delta in HepG2 hepatoma cells","volume":"285","author":"Cao","year":"2010","journal-title":"J. Biol. Chem."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Di Paola, R., Caporarello, N., Marucci, A., Dimatteo, C., Iadicicco, C., Del Guerra, S., Prudente, S., Sudano, D., Miele, C., and Parrino, C. (2011). ENPP1 affects insulin action and secretion: Evidences from in vitro studies. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0019462"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1007\/s00592-013-0458-x","article-title":"Adiponectin increases glucose-induced insulin secretion through the activation of lipid oxidation","volume":"50","author":"Caporarello","year":"2013","journal-title":"Acta Diabetol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00592-019-01462-y","article-title":"The novel loss of function Ile354Val mutation in PPARG causes familial partial lipodystrophy","volume":"57","author":"Padova","year":"2020","journal-title":"Acta Diabetol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/4\/1851\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T10:22:24Z","timestamp":1771237344000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/4\/1851"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,14]]},"references-count":37,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["ijms27041851"],"URL":"https:\/\/doi.org\/10.3390\/ijms27041851","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,14]]}}}